Lead Product(s): Remestemcel-L
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2020
Company initiated Phase 2/3 randomized trial to confirm whether its allogeneic mesenchymal stem cell therapy remestemcel-L provides a survival benefit in moderate/severe ARDS due to COVID-19.